How does a non-optimal tube potential affect radiation dose to the affected person in lumbar backbone radiography?
Introduction: When evaluating the radiation dose to the affected person, the lumbar backbone has one of many highest dose values basically radiography, subsequently the process must be optimised. The purpose of this examine was to analyze the impact of a non-optimal tube potential (66 kV) throughout anteroposterior (AP) lumbar backbone radiography on the radiation dose acquired by the affected person in contrast with the radiation dose when an optimum tube potential (79 kV) is used, in accordance with European tips.
Strategies: This retrospective examine concerned 100 sufferers referred for lumbar radiography in two completely different diagnostic departments. Half of the sufferers have been admitted to a division which used optimum tube potential and the opposite half to the division which used non-optimal tube potential for AP lumbar backbone radiography protocols. The peak and weight of the sufferers have been collected to calculate the physique mass index (BMI) of the sufferers. The picture discipline dimension and dose space product (DAP) values have been collected after every imaging session. The efficient dose and chosen organ dose have been calculated utilizing the PCXMC 2.Zero program.
Outcomes: The outcomes confirmed that a non-optimal tube potential resulted in a major improve within the DAP worth by 360% (p < 0.001) and a major improve within the efficient dose by 160% (p < 0.001). Dose to chose organs as a consequence of non-optimal tube potential elevated from 107% (breasts) as much as 631% (prostate) (p < 0.001). The photographs weren’t assessed utilizing visible grading traits (VGC) evaluation, however the radiologists evaluated all the pictures applicable for diagnostic studying.
Conclusion: Primarily based on our examine’s acknowledged outcomes, we are able to conclude that optimum tube potential use is crucial to realize the ALARA precept.
Implications for follow: The examine exhibits the impact of a non-optimal tube potential on the radiation dose acquired by the affected person throughout radiography of the lumbar backbone. This might affect doable diagnostic departments to think about protocol optimisation as a result of excessive radiation dose acquired by the affected person.
Description: Carbon powder used for preparation of urine samples for use with the Oxalate Quick Test Strips. Quantity: 10 tubes of 50 mg carbon powder.
Description: This mAb recognizes cytokeratin 4, 5, 6, 8, 10, 13, and 18. This is a broad-spectrum antibody which has been reported to differentiate epithelial tumors from non-epithelial tumors. Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis.
Description: This mAb recognizes cytokeratin 4, 5, 6, 8, 10, 13, and 18. This is a broad-spectrum antibody which has been reported to differentiate epithelial tumors from non-epithelial tumors. Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis.
Description: This mAb recognizes cytokeratin 4, 5, 6, 8, 10, 13, and 18. This is a broad-spectrum antibody which has been reported to differentiate epithelial tumors from non-epithelial tumors. Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis.
Description: This mAb recognizes cytokeratin 4, 5, 6, 8, 10, 13, and 18. This is a broad-spectrum antibody which has been reported to differentiate epithelial tumors from non-epithelial tumors. Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis.
Description: Twenty human keratins are resolved with two-dimensional gel electrophoresis into acidic (pI 6.0) subfamilies. This mAb recognizes acidic (Type I or LMW) and basic (Type II or HMW) cytokeratins, including 59kDa (CK4); 58kDa (CK5); 56kDa (CK6); 52kDa (CK8); 56.5kDa (CK10); 53kDa (CK13) and 45kDa (CK18). This is a broad-spectrum mAb which has been reported to differentiate epithelial tumors from non-epithelial tumors. Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis.
Description: Twenty human keratins are resolved with two-dimensional gel electrophoresis into acidic (pI 6.0) subfamilies. This mAb recognizes acidic (Type I or LMW) and basic (Type II or HMW) cytokeratins, including 59kDa (CK4); 58kDa (CK5); 56kDa (CK6); 52kDa (CK8); 56.5kDa (CK10); 53kDa (CK13) and 45kDa (CK18). This is a broad-spectrum mAb which has been reported to differentiate epithelial tumors from non-epithelial tumors. Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis.
Description: Twenty human keratins are resolved with two-dimensional gel electrophoresis into acidic (pI 6.0) subfamilies. This mAb recognizes acidic (Type I or LMW) and basic (Type II or HMW) cytokeratins, including 59kDa (CK4); 58kDa (CK5); 56kDa (CK6); 52kDa (CK8); 56.5kDa (CK10); 53kDa (CK13) and 45kDa (CK18). This is a broad-spectrum mAb which has been reported to differentiate epithelial tumors from non-epithelial tumors. Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis.
Description: Twenty human keratins are resolved with two-dimensional gel electrophoresis into acidic (pI 6.0) subfamilies. This mAb recognizes acidic (Type I or LMW) and basic (Type II or HMW) cytokeratins, including 59kDa (CK4); 58kDa (CK5); 56kDa (CK6); 52kDa (CK8); 56.5kDa (CK10); 53kDa (CK13) and 45kDa (CK18). This is a broad-spectrum mAb which has been reported to differentiate epithelial tumors from non-epithelial tumors. Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis.
Description: Twenty human keratins are resolved with two-dimensional gel electrophoresis into acidic (pI 6.0) subfamilies. This mAb recognizes acidic (Type I or LMW) and basic (Type II or HMW) cytokeratins, including 59kDa (CK4); 58kDa (CK5); 56kDa (CK6); 52kDa (CK8); 56.5kDa (CK10); 53kDa (CK13) and 45kDa (CK18). This is a broad-spectrum mAb which has been reported to differentiate epithelial tumors from non-epithelial tumors. Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis.
Description: Twenty human keratins are resolved with two-dimensional gel electrophoresis into acidic (pI 6.0) subfamilies. This mAb recognizes acidic (Type I or LMW) and basic (Type II or HMW) cytokeratins, including 59kDa (CK4); 58kDa (CK5); 56kDa (CK6); 52kDa (CK8); 56.5kDa (CK10); 53kDa (CK13) and 45kDa (CK18). This is a broad-spectrum mAb which has been reported to differentiate epithelial tumors from non-epithelial tumors. Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis.
Description: Twenty human keratins are resolved with two-dimensional gel electrophoresis into acidic (pI 6.0) subfamilies. This mAb recognizes acidic (Type I or LMW) and basic (Type II or HMW) cytokeratins, including 59kDa (CK4); 58kDa (CK5); 56kDa (CK6); 52kDa (CK8); 56.5kDa (CK10); 53kDa (CK13) and 45kDa (CK18). This is a broad-spectrum mAb which has been reported to differentiate epithelial tumors from non-epithelial tumors. Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis.
Description: Twenty human keratins are resolved with two-dimensional gel electrophoresis into acidic (pI 6.0) subfamilies. This mAb recognizes acidic (Type I or LMW) and basic (Type II or HMW) cytokeratins, including 59kDa (CK4); 58kDa (CK5); 56kDa (CK6); 52kDa (CK8); 56.5kDa (CK10); 53kDa (CK13) and 45kDa (CK18). This is a broad-spectrum mAb which has been reported to differentiate epithelial tumors from non-epithelial tumors. Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis.
Description: Twenty human keratins are resolved with two-dimensional gel electrophoresis into acidic (pI 6.0) subfamilies. This mAb recognizes acidic (Type I or LMW) and basic (Type II or HMW) cytokeratins, including 59kDa (CK4); 58kDa (CK5); 56kDa (CK6); 52kDa (CK8); 56.5kDa (CK10); 53kDa (CK13) and 45kDa (CK18). This is a broad-spectrum mAb which has been reported to differentiate epithelial tumors from non-epithelial tumors. Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis.
Description: Twenty human keratins are resolved with two-dimensional gel electrophoresis into acidic (pI 6.0) subfamilies. This mAb recognizes acidic (Type I or LMW) and basic (Type II or HMW) cytokeratins, including 59kDa (CK4); 58kDa (CK5); 56kDa (CK6); 52kDa (CK8); 56.5kDa (CK10); 53kDa (CK13) and 45kDa (CK18). This is a broad-spectrum mAb which has been reported to differentiate epithelial tumors from non-epithelial tumors. Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis.
Description: Twenty human keratins are resolved with two-dimensional gel electrophoresis into acidic (pI 6.0) subfamilies. This mAb recognizes acidic (Type I or LMW) and basic (Type II or HMW) cytokeratins, including 59kDa (CK4); 58kDa (CK5); 56kDa (CK6); 52kDa (CK8); 56.5kDa (CK10); 53kDa (CK13) and 45kDa (CK18). This is a broad-spectrum mAb which has been reported to differentiate epithelial tumors from non-epithelial tumors. Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis.
Description: Twenty human keratins are resolved with two-dimensional gel electrophoresis into acidic (pI 6.0) subfamilies. This mAb recognizes acidic (Type I or LMW) and basic (Type II or HMW) cytokeratins, including 59kDa (CK4); 58kDa (CK5); 56kDa (CK6); 52kDa (CK8); 56.5kDa (CK10); 53kDa (CK13) and 45kDa (CK18). This is a broad-spectrum mAb which has been reported to differentiate epithelial tumors from non-epithelial tumors. Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis.
Description: Twenty human keratins are resolved with two-dimensional gel electrophoresis into acidic (pI 6.0) subfamilies. This mAb recognizes acidic (Type I or LMW) and basic (Type II or HMW) cytokeratins, including 59kDa (CK4); 58kDa (CK5); 56kDa (CK6); 52kDa (CK8); 56.5kDa (CK10); 53kDa (CK13) and 45kDa (CK18). This is a broad-spectrum mAb which has been reported to differentiate epithelial tumors from non-epithelial tumors. Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis.
Description: Twenty human keratins are resolved with two-dimensional gel electrophoresis into acidic (pI 6.0) subfamilies. This mAb recognizes acidic (Type I or LMW) and basic (Type II or HMW) cytokeratins, including 59kDa (CK4); 58kDa (CK5); 56kDa (CK6); 52kDa (CK8); 56.5kDa (CK10); 53kDa (CK13) and 45kDa (CK18). This is a broad-spectrum mAb which has been reported to differentiate epithelial tumors from non-epithelial tumors. Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis.
Description: Twenty human keratins are resolved with two-dimensional gel electrophoresis into acidic (pI 6.0) subfamilies. This mAb recognizes acidic (Type I or LMW) and basic (Type II or HMW) cytokeratins, including 59kDa (CK4); 58kDa (CK5); 56kDa (CK6); 52kDa (CK8); 56.5kDa (CK10); 53kDa (CK13) and 45kDa (CK18). This is a broad-spectrum mAb which has been reported to differentiate epithelial tumors from non-epithelial tumors. Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis.
Description: Twenty human keratins are resolved with two-dimensional gel electrophoresis into acidic (pI 6.0) subfamilies. This mAb recognizes acidic (Type I or LMW) and basic (Type II or HMW) cytokeratins, including 59kDa (CK4); 58kDa (CK5); 56kDa (CK6); 52kDa (CK8); 56.5kDa (CK10); 53kDa (CK13) and 45kDa (CK18). This is a broad-spectrum mAb which has been reported to differentiate epithelial tumors from non-epithelial tumors. Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis.
Axygen 0.2ml thin walled flat cap PCR tube assorted colours
Description: Corning and Axygen Liquid Handling Equipment; Axypet Pipettors and Motopet Pipet Controller
×
Totally different Cell and Tissue Habits of Micro-/Nano-Tubes and Micro-/Nano-Nets Topographies on Selective Laser Melting Titanium to Improve Osseointegration
Background and goal: Micro-/nano-tubes (TNTs) and micro-/nano-nets (TNNs) are the widespread and good selection in step one of mixed modifications of titanium floor for additional functionalization within the goal of prolonged indications and therapeutic impact. You will need to acknowledge the respective biologic reactions of these two substrates for guiding a biologically primarily based first-step choice.
Supplies and strategies: TNTs have been produced by anodic oxidation and TNNs have been shaped by alkali-heat therapy. The unique selective laser melting (SLM) titanium floor was set as management. Floor characterization was evaluated by scanning electron microscopy, floor roughness, and water contact angle measurements. Osteoclastogenesis and osteogenesis have been measured. MC3T3-E1 cells and RAW 264.7 cells have been used for in vitro assay when it comes to adhesion, proliferation, and differentiation. In vivo assessments have been taken on Beagle canines with micro-CT and histological evaluation.
Outcomes: TNN and TNT teams carried out decreased roughness and elevated hydrophilicity in contrast with SLM group. For organic detections, the best ALP exercise and osteogenesis-related genes expression have been noticed in TNT group adopted by TNN group (P <0.05). Apparently, in terms of the osteoclastogenesis, TNNs displayed lowest TRAP exercise and osteoclastogenesis-related genes expression and TNTs have been decrease than SLM however increased than TNNs (P <0.05). BV/TV round implants was highest in TNT group after four weeks (P <0.05). HE, ALP and TRAP staining confirmed that osteogenic and osteoclastic exercise round TNTs have been each increased than TNNs (P <0.05).
Conclusion: TNNs and TNTs have twin benefits in promotion of osteogenesis and inhibition of osteoclastogenesis. Moreover, TNNs confirmed higher functionality in inhibiting osteoclast exercise whereas TNTs facilitated stronger osteogenesis. Our outcomes implied that TNT substrates would take benefit in early software after implantation, whereas illnesses with inappropriate osteoclast exercise would favor TNN substrates, which can information a biologically primarily based first-step choice on mixed modification for various scientific functions.
PARP1 Is Focused by miR-519a-3p and Promotes the Migration, Invasion, and Tube Formation of Ovarian Most cancers Cells
Background: Poly ADP-ribose polymerase 1 (PARP1) has been found to be implicated in ovarian most cancers (OC), however its interplay with microRNA (miR)-519a-3p remained poorly understood. This examine aimed to uncover their roles and interactions in OC.
Supplies and Strategies: Scientific tissue from OC sufferers and adjoining regular tissue have been collected, and the survival charges of OC sufferers with excessive or low PARP1 expression have been analyzed by Kaplan-Meier curve. After transfection, OC cell viability, migration, and tube formation have been detected with cell counting kit-8 (CCK-8) assay, scratch assay, and tube formation assay, respectively. Goal gene of miR-519a-3p and potential binding websites between them have been predicted with TargetScan and confirmed utilizing dual-luciferase reporter assay. Relative expressions of miR-519a-3p, PARP1, E-cadherin, N-cadherin, SNAIL, vascular endothelial progress issue (VEGF), and p53 have been measured by quantitative real-time polymerase chain response and Western blot as wanted.
Outcomes: PARP1 expression was upregulated in OC, which was associated to poor prognosis of OC sufferers. Silencing PARP1 decreased PARP1 expression and suppressed viability, migration, invasion, and tube formation in OC cells, whereas overexpressed PARP1 did the alternative. PARP1 was the goal gene of miR-519a-3p, and it reversed the consequences of miR-519a-3p on the migration, invasion, and tube formation of OC cells by upregulating the expressions of PAR, PARP1, N-cadherin, SNAIL, and VEGF and downregulating these of E-cadherin and p53.
Conclusion: PARP1, a goal gene of miR-519a-3p, promoted the migration, invasion, and tube formation of OC cells, offering a doable therapeutic goal for therapy of OC sufferers.
Description: Carbon powder used for preparation of urine samples for use with the Oxalate Quick Test Strips. Quantity: 10 tubes of 50 mg carbon powder.
Description: This antibody recognizes multi cytokeratins: 4, 5, 6, 8, 10, 13, and 18. It is a broad-spectrum cytokeratin antibody which has been reported to be used to differentiate epithelial tumors from non-epithelial tumors. Many studies have shown the usefulness of cytokeratin markers in cancer research and tumor diagnosis.
Description: This antibody recognizes multi cytokeratins: 4, 5, 6, 8, 10, 13, and 18. It is a broad-spectrum cytokeratin antibody which has been reported to be used to differentiate epithelial tumors from non-epithelial tumors. Many studies have shown the usefulness of cytokeratin markers in cancer research and tumor diagnosis.
Description: This antibody recognizes multi cytokeratins: 4, 5, 6, 8, 10, 13, and 18. It is a broad-spectrum cytokeratin antibody which has been reported to be used to differentiate epithelial tumors from non-epithelial tumors. Many studies have shown the usefulness of cytokeratin markers in cancer research and tumor diagnosis.
Description: This antibody recognizes multi cytokeratins: 4, 5, 6, 8, 10, 13, and 18. It is a broad-spectrum cytokeratin antibody which has been reported to be used to differentiate epithelial tumors from non-epithelial tumors. Many studies have shown the usefulness of cytokeratin markers in cancer research and tumor diagnosis.
Description: A Monoclonal antibody against Human ITPR1 / IP3 Receptor Type 1 (clone S24-18). The antibodies are raised in Mouse and are from clone S24-18. This antibody is applicable in WB and IHC-P, IP
Description: This mAb recognizes cytokeratin 4, 5, 6, 8, 10, 13, and 18. This is a broad-spectrum antibody which has been reported to differentiate epithelial tumors from non-epithelial tumors. Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis.
Description: This mAb recognizes cytokeratin 4, 5, 6, 8, 10, 13, and 18. This is a broad-spectrum antibody which has been reported to differentiate epithelial tumors from non-epithelial tumors. Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis.
Description: This mAb recognizes cytokeratin 4, 5, 6, 8, 10, 13, and 18. This is a broad-spectrum antibody which has been reported to differentiate epithelial tumors from non-epithelial tumors. Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis.
Description: This mAb recognizes cytokeratin 4, 5, 6, 8, 10, 13, and 18. This is a broad-spectrum antibody which has been reported to differentiate epithelial tumors from non-epithelial tumors. Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis.
Description: Twenty human keratins are resolved with two-dimensional gel electrophoresis into acidic (pI 6.0) subfamilies. This mAb recognizes acidic (Type I or LMW) and basic (Type II or HMW) cytokeratins, including 59kDa (CK4); 58kDa (CK5); 56kDa (CK6); 52kDa (CK8); 56.5kDa (CK10); 53kDa (CK13) and 45kDa (CK18). This is a broad-spectrum mAb which has been reported to differentiate epithelial tumors from non-epithelial tumors. Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis.
Description: Twenty human keratins are resolved with two-dimensional gel electrophoresis into acidic (pI 6.0) subfamilies. This mAb recognizes acidic (Type I or LMW) and basic (Type II or HMW) cytokeratins, including 59kDa (CK4); 58kDa (CK5); 56kDa (CK6); 52kDa (CK8); 56.5kDa (CK10); 53kDa (CK13) and 45kDa (CK18). This is a broad-spectrum mAb which has been reported to differentiate epithelial tumors from non-epithelial tumors. Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis.
Description: Twenty human keratins are resolved with two-dimensional gel electrophoresis into acidic (pI 6.0) subfamilies. This mAb recognizes acidic (Type I or LMW) and basic (Type II or HMW) cytokeratins, including 59kDa (CK4); 58kDa (CK5); 56kDa (CK6); 52kDa (CK8); 56.5kDa (CK10); 53kDa (CK13) and 45kDa (CK18). This is a broad-spectrum mAb which has been reported to differentiate epithelial tumors from non-epithelial tumors. Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis.
Description: Twenty human keratins are resolved with two-dimensional gel electrophoresis into acidic (pI 6.0) subfamilies. This mAb recognizes acidic (Type I or LMW) and basic (Type II or HMW) cytokeratins, including 59kDa (CK4); 58kDa (CK5); 56kDa (CK6); 52kDa (CK8); 56.5kDa (CK10); 53kDa (CK13) and 45kDa (CK18). This is a broad-spectrum mAb which has been reported to differentiate epithelial tumors from non-epithelial tumors. Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis.
Description: Twenty human keratins are resolved with two-dimensional gel electrophoresis into acidic (pI 6.0) subfamilies. This mAb recognizes acidic (Type I or LMW) and basic (Type II or HMW) cytokeratins, including 59kDa (CK4); 58kDa (CK5); 56kDa (CK6); 52kDa (CK8); 56.5kDa (CK10); 53kDa (CK13) and 45kDa (CK18). This is a broad-spectrum mAb which has been reported to differentiate epithelial tumors from non-epithelial tumors. Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis.
Description: Twenty human keratins are resolved with two-dimensional gel electrophoresis into acidic (pI 6.0) subfamilies. This mAb recognizes acidic (Type I or LMW) and basic (Type II or HMW) cytokeratins, including 59kDa (CK4); 58kDa (CK5); 56kDa (CK6); 52kDa (CK8); 56.5kDa (CK10); 53kDa (CK13) and 45kDa (CK18). This is a broad-spectrum mAb which has been reported to differentiate epithelial tumors from non-epithelial tumors. Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis.
Description: Twenty human keratins are resolved with two-dimensional gel electrophoresis into acidic (pI 6.0) subfamilies. This mAb recognizes acidic (Type I or LMW) and basic (Type II or HMW) cytokeratins, including 59kDa (CK4); 58kDa (CK5); 56kDa (CK6); 52kDa (CK8); 56.5kDa (CK10); 53kDa (CK13) and 45kDa (CK18). This is a broad-spectrum mAb which has been reported to differentiate epithelial tumors from non-epithelial tumors. Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis.
Description: Twenty human keratins are resolved with two-dimensional gel electrophoresis into acidic (pI 6.0) subfamilies. This mAb recognizes acidic (Type I or LMW) and basic (Type II or HMW) cytokeratins, including 59kDa (CK4); 58kDa (CK5); 56kDa (CK6); 52kDa (CK8); 56.5kDa (CK10); 53kDa (CK13) and 45kDa (CK18). This is a broad-spectrum mAb which has been reported to differentiate epithelial tumors from non-epithelial tumors. Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis.
Description: Twenty human keratins are resolved with two-dimensional gel electrophoresis into acidic (pI 6.0) subfamilies. This mAb recognizes acidic (Type I or LMW) and basic (Type II or HMW) cytokeratins, including 59kDa (CK4); 58kDa (CK5); 56kDa (CK6); 52kDa (CK8); 56.5kDa (CK10); 53kDa (CK13) and 45kDa (CK18). This is a broad-spectrum mAb which has been reported to differentiate epithelial tumors from non-epithelial tumors. Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis.
Description: Twenty human keratins are resolved with two-dimensional gel electrophoresis into acidic (pI 6.0) subfamilies. This mAb recognizes acidic (Type I or LMW) and basic (Type II or HMW) cytokeratins, including 59kDa (CK4); 58kDa (CK5); 56kDa (CK6); 52kDa (CK8); 56.5kDa (CK10); 53kDa (CK13) and 45kDa (CK18). This is a broad-spectrum mAb which has been reported to differentiate epithelial tumors from non-epithelial tumors. Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis.
Description: Twenty human keratins are resolved with two-dimensional gel electrophoresis into acidic (pI 6.0) subfamilies. This mAb recognizes acidic (Type I or LMW) and basic (Type II or HMW) cytokeratins, including 59kDa (CK4); 58kDa (CK5); 56kDa (CK6); 52kDa (CK8); 56.5kDa (CK10); 53kDa (CK13) and 45kDa (CK18). This is a broad-spectrum mAb which has been reported to differentiate epithelial tumors from non-epithelial tumors. Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis.
Description: Twenty human keratins are resolved with two-dimensional gel electrophoresis into acidic (pI 6.0) subfamilies. This mAb recognizes acidic (Type I or LMW) and basic (Type II or HMW) cytokeratins, including 59kDa (CK4); 58kDa (CK5); 56kDa (CK6); 52kDa (CK8); 56.5kDa (CK10); 53kDa (CK13) and 45kDa (CK18). This is a broad-spectrum mAb which has been reported to differentiate epithelial tumors from non-epithelial tumors. Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis.
Description: Twenty human keratins are resolved with two-dimensional gel electrophoresis into acidic (pI 6.0) subfamilies. This mAb recognizes acidic (Type I or LMW) and basic (Type II or HMW) cytokeratins, including 59kDa (CK4); 58kDa (CK5); 56kDa (CK6); 52kDa (CK8); 56.5kDa (CK10); 53kDa (CK13) and 45kDa (CK18). This is a broad-spectrum mAb which has been reported to differentiate epithelial tumors from non-epithelial tumors. Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis.
Description: Twenty human keratins are resolved with two-dimensional gel electrophoresis into acidic (pI 6.0) subfamilies. This mAb recognizes acidic (Type I or LMW) and basic (Type II or HMW) cytokeratins, including 59kDa (CK4); 58kDa (CK5); 56kDa (CK6); 52kDa (CK8); 56.5kDa (CK10); 53kDa (CK13) and 45kDa (CK18). This is a broad-spectrum mAb which has been reported to differentiate epithelial tumors from non-epithelial tumors. Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis.
Description: Twenty human keratins are resolved with two-dimensional gel electrophoresis into acidic (pI 6.0) subfamilies. This mAb recognizes acidic (Type I or LMW) and basic (Type II or HMW) cytokeratins, including 59kDa (CK4); 58kDa (CK5); 56kDa (CK6); 52kDa (CK8); 56.5kDa (CK10); 53kDa (CK13) and 45kDa (CK18). This is a broad-spectrum mAb which has been reported to differentiate epithelial tumors from non-epithelial tumors. Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis.
Description: Twenty human keratins are resolved with two-dimensional gel electrophoresis into acidic (pI 6.0) subfamilies. This mAb recognizes acidic (Type I or LMW) and basic (Type II or HMW) cytokeratins, including 59kDa (CK4); 58kDa (CK5); 56kDa (CK6); 52kDa (CK8); 56.5kDa (CK10); 53kDa (CK13) and 45kDa (CK18). This is a broad-spectrum mAb which has been reported to differentiate epithelial tumors from non-epithelial tumors. Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis.
Axygen 0.2ml thin walled flat cap PCR tube assorted colours
Description: Quantitativesandwich ELISA kit for measuring Rat Keratin, type I cytoskeletal 18 (KRT18) in samples from serum, plasma, tissue homogenates. A new trial version of the kit, which allows you to test the kit in your application at a reasonable price.
Rat Keratin, type I cytoskeletal 18(KRT18) ELISA kit
Description: Quantitativesandwich ELISA kit for measuring Rat Keratin, type I cytoskeletal 18(KRT18) in samples from serum, plasma, tissue homogenates. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits.
Human papillomavirus type 18 (HPV18) antibody (IgM) ELISA kit
Description: Quantitativesandwich ELISA kit for measuring Human papillomavirus type 18 (HPV18) antibody (IgM) in samples from serum, plasma. A new trial version of the kit, which allows you to test the kit in your application at a reasonable price.
Human papillomavirus type 18 (HPV18) antibody (IgM) ELISA kit
Description: Quantitativesandwich ELISA kit for measuring Human papillomavirus type 18 (HPV18) antibody (IgM) in samples from serum, plasma. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits.
Mouse Keratin, type I cytoskeletal 18(KRT18) ELISA kit
Description: Quantitativesandwich ELISA kit for measuring Mouse Keratin, type I cytoskeletal 18 (KRT18) in samples from serum, plasma. A new trial version of the kit, which allows you to test the kit in your application at a reasonable price.
Mouse Keratin, type I cytoskeletal 18(KRT18) ELISA kit
Description: Quantitativesandwich ELISA kit for measuring Mouse Keratin, type I cytoskeletal 18(KRT18) in samples from serum, plasma. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits.
Recombinant Human Papilloma Virus Type 18 (HPV18), L1 Protein
Description: Enzyme-linked immunosorbent assay kit for quantification of Mouse Keratin, type I cytoskeletal 18 in samples from serum, plasma, tissue homogenates and other biological fluids.
ELISA kit for Human Keratin, type I cytoskeletal 18
Description: Enzyme-linked immunosorbent assay kit for quantification of Human Keratin, type I cytoskeletal 18 in samples from serum, plasma, tissue homogenates and other biological fluids.
Mouse Krt18/ Keratin, type I cytoskeletal 18 ELISA Kit
